Nectar Lifesciences Ltd. (NECLIFE) AI Stock Analysis

• Market Cap: ₹2.46B
• Dividend Yield: N/A
• Average Volume (3M): 34.32K
• Price to Earnings (P/E): 7.6
• Beta (1Y): 0.92
• Revenue Growth: -30.27%
• EPS Growth: -3470.06%
• Country: IN
• Employees: 1,686
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.64
• Shares Outstanding: 224,260,970
• 10 Day Avg. Volume: 25,321
• 30 Day Avg. Volume: 34,323
• PEG Ratio: <0.01
• Price to Book (P/B): 0.56
• Price to Sales (P/S): 0.32
• P/FCF Ratio: 4.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: ₹11.00 ▼(-39.73% Downside)
• Action: Reiterated Date: 01/20/26
• Date: Action: Reiterated 01/20/26

The score is held back primarily by weak financial performance (profitability and growth pressure despite a relatively stable capital structure) and bearish technicals (below key moving averages with negative MACD and oversold momentum). Valuation provides limited support given the negative P/E and lack of dividend data.

Positive Factors

Diversified Business Model

Nectar sells APIs, finished dosage formulations and offers contract manufacturing, creating multiple revenue streams. This structural diversification reduces reliance on a single end market, helps absorb demand swings across segments, and supports export/customer continuity over months.

Stable Capital Structure

The balance sheet shows moderate leverage and a stable equity ratio, providing financial flexibility. A balanced debt profile supports working capital and facility upkeep in a capital-intensive pharma business and lowers near-term refinancing risk over the coming quarters.

Improving Cash Generation

Operating cash flow showed notable recent improvement, indicating the company can generate cash from operations intermittently. If sustained, improved cash conversion helps fund inventory and capex internally, reducing dependence on external financing over the medium term.

Negative Factors

Sharp Revenue Decline

Revenues have contracted sharply (~57% decline), eroding scale critical for pharma manufacturing. Lower volumes impair fixed-cost absorption, reduce negotiating leverage with suppliers/customers, and make margin recovery and growth restoration materially harder over the next several quarters.

Weak Profitability and Margins

The company reports a negative net profit margin and declining gross margins, signaling structural pressure on pricing or costs. Persistent margin weakness limits reinvestment capacity, hurts competitive positioning in generics, and undermines sustainable returns to shareholders.

Volatile Cash Flows & Poor ROE

Free cash flow has been inconsistent despite recent improvement, while ROE remains negative, indicating returns below shareholder capital. Combined volatility and poor returns constrain the company’s ability to deleverage, invest in capacity, or fund product development sustainably.

Nectar Lifesciences Ltd. Business Overview & Revenue Model

Company Description

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

How the Company Makes Money

Nectar Lifesciences makes money primarily by manufacturing and selling pharmaceutical products to customers such as drug marketers, wholesalers/distributors, and other pharmaceutical companies. Key revenue streams include: (1) Sale of finished dosage formulations (e.g., tablets/capsules/injectables) where revenue is generated per unit supplied under the company’s own product sales and/or supply arrangements; (2) Sale of APIs/intermediates where revenue is earned from bulk pharmaceutical ingredients supplied to formulation companies that use them as inputs; and (3) Contract manufacturing/third-party manufacturing services (if and when utilized) where the company earns manufacturing fees and/or product supply revenues under customer contracts. Earnings are influenced by volumes shipped, product mix (higher- vs lower-margin products), manufacturing utilization, raw-material/input costs, regulatory compliance status for manufacturing sites, and the company’s ability to serve export customers through required quality certifications. Specific disclosures on the relative contribution of each stream, major customers, and named strategic partnerships are null.

Nectar Lifesciences Ltd. Financial Statement Overview

Summary

Overall financials are weak-to-mixed: income statement shows negative net profit margin and declining revenue growth, balance sheet is relatively stable with moderate leverage but negative recent ROE, and cash flows are volatile with only recent improvement.

Income Statement

Nectar Lifesciences Ltd. has experienced significant volatility in its income statement metrics. The company reported a negative net profit margin and declining revenue growth rate in the latest period, indicating challenges in maintaining profitability and growth. The gross profit margin has also decreased over time, reflecting potential issues in cost management or pricing power. However, there were periods of positive EBIT and EBITDA margins, suggesting some operational efficiency during certain years.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. However, the return on equity has been negative in recent periods, reflecting challenges in generating returns for shareholders. The equity ratio remains stable, suggesting a solid capital structure despite profitability issues.

Cash Flow

Cash flow analysis reveals fluctuating free cash flow growth, with a notable improvement in the latest period. The operating cash flow to net income ratio indicates some level of cash generation efficiency, although the free cash flow to net income ratio has been inconsistent. Overall, the cash flow position shows potential for improvement but remains volatile.

Breakdown	TTM	Jun 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	11.70B	16.70B	16.84B	15.24B	16.69B	15.43B
Gross Profit	671.45M	3.02B	4.82B	579.91M	2.99B	2.58B
EBITDA	-1.71B	-245.66M	1.69B	994.97M	1.61B	612.51M
Net Income	-3.61B	-1.14B	49.95M	-241.83M	250.47M	-732.64M
Balance Sheet
Total Assets	18.15B	20.47B	21.91B	21.89B	23.91B	23.88B
Cash, Cash Equivalents and Short-Term Investments	139.72M	272.63M	203.01M	178.94M	182.35M	259.58M
Total Debt	4.59B	5.82B	6.36B	7.54B	8.60B	9.03B
Total Liabilities	10.98B	10.91B	11.22B	11.25B	13.03B	13.26B
Stockholders Equity	7.17B	9.56B	10.69B	10.65B	10.88B	10.62B
Cash Flow
Free Cash Flow	1.44B	1.26B	1.95B	1.04B	700.35M	-98.62M
Operating Cash Flow	1.53B	1.69B	2.25B	1.34B	950.05M	213.79M
Investing Cash Flow	-82.31M	-419.30M	-170.25M	517.04M	166.44M	-286.24M
Financing Cash Flow	-1.58B	-1.28B	-2.05B	-1.86B	-1.19B	114.90M

Nectar Lifesciences Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NECLIFE, the sentiment is Negative. The current price of 18.25 is above the 20-day moving average (MA) of 11.77, above the 50-day MA of 13.57, and above the 200-day MA of 16.49, indicating a bearish trend. The MACD of -0.76 indicates Negative momentum. The RSI at 26.73 is Positive, neither overbought nor oversold. The STOCH value of 18.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NECLIFE.

Nectar Lifesciences Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	79 Outperform	₹11.46B	10.01	―	―	13.32%	218.38%
SAKAR	66 Neutral	₹11.51B	22.21	―	―	24.20%	55.01%
ZIMLAB	63 Neutral	₹3.31B	19.99	―	―	-5.82%	-59.22%
INDSWFTLAB	61 Neutral	₹11.60B	18.86	―	―	-37.70%	-19.79%
MEDICAMEQ	55 Neutral	₹3.54B	56.53	―	0.26%	-9.16%	49.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	46 Neutral	₹2.46B	7.63	―	―	-30.27%	-3470.06%

Nectar Lifesciences Ltd. Corporate Events

Nectar Lifesciences Shareholders Clear Key Board and Governance Changes via Postal Ballot

Nectar Lifesciences Ltd. has announced the results of a recent postal ballot, conducted via remote e-voting between January 30 and February 28, 2026, to seek shareholder approval on key corporate resolutions. Based on the scrutinizer’s report, all proposed resolutions were passed with the requisite majority, with approvals deemed effective as of February 28, 2026.

Shareholders approved the appointment of Mr. Sushil Kapoor as a director liable to retire by rotation and as a whole-time Director (Finance) for a three-year term, strengthening the company’s financial leadership. They also adopted a new memorandum of association with an amended object clause, indicating a potential strategic realignment of the company’s business scope and corporate objectives, which may impact its future operations and market positioning.

Nectar Lifesciences Says Subsidiary Inactive, Standalone and Consolidated Results Aligned

Nectar Lifesciences has clarified to the National Stock Exchange that its only wholly owned subsidiary, NECLIFE PT, UNIPESSOAL LDA, recorded no business activity, revenue, or expenditure during the quarter ended September 30, 2025. As a result, the company’s standalone and consolidated financial results for the quarter are identical, a position supported by the independent auditors’ review report, and the company has asked the exchange to treat the matter as closed.

Nectar Lifesciences Closes Trading Window Ahead of December Quarter Results

Nectar Lifesciences Ltd. has announced that, in compliance with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct, it will close its trading window for designated persons and their immediate relatives from January 1, 2026 until 48 hours after the declaration of its financial results for the period ended December 31, 2025. The move restricts insiders from trading in the company’s securities during the sensitive period around quarterly financial disclosures, reinforcing regulatory compliance and governance standards for investors and market participants.

Nectar Lifesciences to Divest Capsule Unit to Capnest Health Care in INR 19.9 Crore Slump Sale

Nectar Lifesciences Ltd. has entered into a Business Transfer Agreement with Capnest Health Care Private Limited to sell its Empty Hard Gelatin Capsule manufacturing, distribution and marketing unit located at Bhatoli Kalan, Baddi, Himachal Pradesh, on a slump sale and going-concern basis. The transaction, valued at INR 19.9 crore along with the takeover of related receivables, payables and other working capital adjustments, involves a business that contributed 1.28% of the company’s FY25 revenue and 2.25% of its net worth, and is expected to close on or before April 30, 2026; the buyer is unrelated to the promoter group, indicating a non-related-party divestment of a relatively small unit as the company fine-tunes its portfolio and capital allocation.